A study of leptin and its gene 2548 G/A Rs7799039 single-nucleotide polymorphisms in Egyptian children: A single-center experience

Mohamed, Amal Ahmed; Ahmed, Hoda Hegazy; ElSadek, Sanaa Mohammed; Mohamed, Rasha S.; Elamir, Reham Y; Salah, Wafaa; Sultan, Eman A.; El-Hassib, Dalia Mohamed Abd; Fouad, Hanan

doi:10.1016/j.clinre.2021.101724

Cited by 5 publications

(1 citation statement)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HCC is considered the fifth most abundant type of tumor worldwide and the third most lethal cancer, causing 600,000 deaths each year. 4 , 5 Ultrasound is the most widely used imaging test for NAFLD diagnosis, but its sensitivity decreases if <30% of the liver is affected by steatosis. Additionally, computed tomography (CT scan) is accurate for diagnosing moderate-to-severe liver steatosis; however, it is not accurate for detecting mild steatosis.…”

Section: Introductionmentioning

confidence: 99%

Pro-Neurotensin as a Potential Novel Diagnostic Biomarker for Detection of Nonalcoholic Fatty Liver Disease

Mohamed¹,

Abo-Elmatty²,

Ezzat³

et al. 2022

DMSO

View full text Add to dashboard Cite

Background and Aims Currently, liver biopsy is the gold standard method for diagnosis of non-alcoholic fatty liver severity. It is critical to develop non-invasive diagnostic method to diagnose nonalcoholic fatty liver rather than invasive techniques. Our case–control study was to address the value of circulating miRNA-122 and serum pro-neurotensin as a potential non-invasive biomarker for the diagnosis of non-alcoholic fatty acid diseases. Methods Clinical assessment, laboratory investigations, and anthropometric measurements were reported for 157 patients with proven NAFLD. Apparently, healthy participants (n=100) were enrolled as a control group. Serum samples were tested for micro-RNAs−122 and pro-neurotensin. Results Compared with the control subjects, both mi-RNA-122 and serum proneurotensin levels were increased in NAFLD (p<0.001) and at a cut-off ≥6.83, mi-RNA-122 had 51.0% sensitivity, 70.0% specificity to differentiate NAFLD from healthy controls, while serum proneurotensin had 80.0% sensitivity and 80.0% specificity at a cutoff ≥108. Conclusion The circulating pro-neurotensin might be used as a novel biomarker for diagnosis of patients with NAFLD, wherefore the integration of a circulating mi-RNA-122 and serum pro-neurotensin could be beneficial to diagnose NAFLD cases. Large-scale studies are needed to investigate the possible role of mi-RNA-122 and pro-neurotensin in the development, progression, and prognosis of NAFLD and NASH.

show abstract

Section: Introductionmentioning

confidence: 99%